Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

A growing body of evidence supports the hypothesis that the pathophysiology of seborrhoeic dermatitis has a potentially causative neurogenic inflammatory aspect. ASF1057 is a new drug that acts through a modulation of neurogenic inflammation through important complementary mechanisms of action. This study will test the efficacy and safety of ASF1057 in the treatment of patients with seborrhoeic dermatitis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astion Pharma A/S

Criteria

Inclusion Criteria:

• Clinical diagnosis of moderate to severe seborrhoeic dermatitis

Exclusion Criteria:

• Other active skin diseases

• Use of certain systemic and topical treatments

• Extensive sun exposure